

ImpediMed Limited - Appendix 4E
ABN 65 089 705 144
Preliminary final report

1 Current Financial Period Ended: 30 June 2015
Previous Corresponding Reporting Period: 30 June 2014

The information contained in this document should be read in conjunction with the ImpediMed Limited Annual Financial Report for the year ended 30 June 2015 ("2015 Financial Report") and any public announcements made by ImpediMed Limited and its controlled entities during the year in accordance with continuous disclosure obligations arising under the ASX Listing Rules.

2 Results for announcement to the market

| | Current reporting period \$000 | Previous corresponding period \$000 |
|--|--------------------------------------|--|
| 2.1 Revenue from ordinary activities | \$ (4,927) | \$ (3,578) |
| Increase (decrease) in revenue (\$000): | | \$ 1,349 |
| Percentage increase (decrease): | | 38% |
| <p>Note : Revenue related to goods and services increased for the year ended 30 June 2015 to \$4.9 million (2014 \$3.6 million), an increase of \$1.3 million year over year. The change by operating segment was an increase of \$0.5 million in medical, and a \$0.8 million increase in test & measurement. The \$0.5 million increase in the medical segment was due to a \$0.1 million increase in body composition and veterinary products, while total lymphoedema product revenue for the Group increased by \$0.4 million, or 28% year over year.</p> | | |
| 2.2 Profit/(loss) from ordinary activities after tax attributable to members | (14,797) | (7,935) |
| Increase/(decrease) in profit from ordinary activities after tax attributable to members (\$000): | | \$ (6,862) |
| Percentage increase/(decrease): | | -86% |
| <p>Note : Refer to the Directors' Report for a more extensive analysis; however, in summary, in addition to the increase in revenue above:</p> <ul style="list-style-type: none"> - salaries and benefits expense increased by \$4.4 million - research and development expenses increased by \$0.6 million - consultants and professional fees increased by \$0.5 million - advertising and promotion expense increased by \$0.8 million - travel expense increased by \$0.5 million | | |
| 2.3 Net profit/(loss) for the period attributable to members | (14,797) | (7,935) |
| Increase/(decrease) in net profit for the period attributable to members (\$000): | | \$ (6,862) |
| Percentage increase/(decrease): | | -86% |
| <p>Note: Refer to 2.2 above and to the Directors' Report in the 2015 Financial Report.</p> | | |

3 Dividends

3.1 Dividends **Nil**

There were no dividends declared and paid during the reporting period on ordinary shares.
There were no dividends proposed and not yet recognised as a liability during the reporting period.

3.2 Dividend Record Date **Not applicable**

| | | |
|--|-----------------------------|-------------------------------------|
| 4 Financial Statements | | |
| 4.1 Statement of comprehensive income Refer to the Consolidated Statement of Comprehensive Income in the 2015 Financial Report. | | |
| 4.2 Statement of financial position Refer to the Consolidated Balance Sheet in the 2015 Financial Report. | | |
| 4.3 Statement of cash flows Refer to the Consolidated Cash Flow Statement in the 2015 Financial Report. | | |
| 4.4 Statement of retained earnings Refer to the Consolidated Statement of Changes in Equity in the 2015 Financial Report for movements in retained earnings. | | |
| 5 Net tangible assets per security | | |
| | Current reporting period | Previous corresponding period |
| 5.1 Net tangible assets (\$000) | 32,429 | 11,567 |
| Issued share capital at reporting date (\$000) | 147,349 | 116,593 |
| | Current reporting period | Previous corresponding period |
| Number of shares on issue at reporting date | 293,287,840 | 238,672,802 |
| Net tangible assets per security | \$ 0.11 | \$ 0.05 |
| 6 Earnings per security | | |
| | Current reporting period | Previous corresponding period |
| 6.1 Weighted average number of ordinary shares (excluding reserved shares) for basic earnings per share (EPS) | 268,288,850 | 195,605,935 |
| Loss per share from continued operations | | |
| Basic EPS | \$ - | \$ - |
| Loss per share from profit attributable to ordinary shares | | |
| Basic EPS | \$ - | \$ - |
| Diluted earnings per share has been determined to be the same as basic earnings per share as the actual calculation is anti-dilutive for both periods presented. | | |
| Refer to Note 1 - Earnings per share in the Annual Financial Report for the year ended 30 June 2015 for additional information pertaining to EPS for the current reporting period. | | |
| 7 Acquisitions and divestments There were no entities over which control has been gained or lost during the reporting period. | | |
| 8 Foreign entities Not applicable. | | |
| 9 Associates and joint ventures Not applicable. | | |
| 10 Commentary on results for the financial year Refer to the Annual Financial Report for the year ended 30 June 2015. | | |
| 11 Results of segments Refer to Note 3 - Segment reporting in the Annual Financial Report for the year ended 30 June 2015 for additional information pertaining to segment results for the current reporting period. | | |
| 12 Audited Report The report is based on audited accounts which are not subject to dispute, modification, or qualification. | | |